Acute renal failure following kidney transplantation associated with myoglobinuria in patients treated with rapamycin

Transplantation

Volumn 82, Issue 5, 2006, Pages 645-650

  Pelletier, Ronald ^a,c   Nadasdy, Tibor ^a   Nadasdy, Gyongyi ^a   Satoskar, Anjali ^a   Tewari, Arun Kumar ^b   Cotrill, Jeffrey ^b   Henry, Mitchell ^a   Rajab, Amer ^a   Ferguson, Ronald ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Acute renal failure; Kidney transplantation; Myoglobinuria; Rapamycin

Indexed keywords

ATORVASTATIN; BASILIXIMAB; CREATINE KINASE; CYCLOSPORIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYOGLOBIN; PREDNISONE; RAPAMYCIN; SIMVASTATIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ADOLESCENT; ADULT; AGED; BACTERIAL INFECTION; BLOOD LEVEL; CANDIDIASIS; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIALYSIS; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; FEMALE; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE INFECTION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE COMPLEX NEPHRITIS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MYOGLOBINURIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RHABDOMYOLYSIS; SEPSIS; TREATMENT OUTCOME; URINARY TRACT INFECTION; VALIDATION PROCESS; WESTERN BLOTTING;

BIOPSY; HUMANS; IMMUNOBLOTTING; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY FAILURE, ACUTE; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; MYOGLOBIN; PANCREAS TRANSPLANTATION; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 33748690744     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000230310.27913.01     Document Type: Review

References (18)

1. Zager RA. Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int 1996; 49(2): 314.
2. Allison RC, Bedsole DL. The other medical causes of rhabdomyolysis. Am J Med Sci 2003; 326(2): 79.
3. Wortmann RL. Lipid-lowering agents and myopathy. Curr Opin Rheumatol 2002; 14(6): 643.
4. Herrera GA. Myoglobin and the kidney: an overview. Ultrastruct Pathol 1994; 18(1-2): 113.
5. Nadasdy T, Racusen LC. Renal injury caused by therapeutic and diagnostic agents and abuse of analgesics and narcotics. In: Jennette JC, Olson JL, Schwartz MM, Silva FG. Heptinstall's Pathology of the Kidney, 5th ed. Philadelphia: Lippincott-Raven, 1998: 785.
6. Arthur JM, Thongboonkerd V, Scherzer JA, et al. Differential expression of proteins in renal cortex and medulla: a proteomic approach. Kidney Int 2002; 62(4): 1314.
7. Smith KD, Wrenshall LE, Nicosia RF, et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003; 14(4): 1037.
8. Simon JF, Swanson SJ, Agodoa LY, et al. Induction sirolimus and delayed graft function after deceased donor kidney transplantation in the United States. Am J Nephrol 2004; 24(4): 393.
9. McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3(4): 416.
10. Stallone G, Di Paolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 2004; 15(1): 228.
11. McTaggart RA, Tomlanovich S, Bostrom A, et al. Comparison of outcomes after delayed graft function: sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens. Transplantation 2004; 78(3): 475.
12. Lawsin L, Light JA. Severe acute renal failure after exposure to sirolimus-tacrolimus in two living donor kidney recipients. Transplantation 2003; 75(1): 157.
13. Bolster DR, Jefferson LS, Kimball SR. Regulation of protein synthesis associated with skeletal muscle hypertrophy by insulin-, amino-acid and exercise-induced signalling. Proc Nutr Soc 2004; 63(2): 351.
14. Latres E, Amini AR, Amini AA, et al. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem 2005; 280(4): 2737.
15. Tirado OM, Mateo-Lozano S, Notario V. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity. Oncogene 2005; 24(20): 3348.
16. Schachner T, Oberhuber A, Zou Y, et al. Rapamycin treatment is associated with an increased apoptosis rate in experimental vein grafts. Eur J Cardiothorac Surg 2005; 27(2): 302.
17. Avellino R, Romano S, Parasole R, et al. Rapamycin Stimulates Apoptosis of Childhood Acute Lymphoblastic Leukemia Cells. Blood 2005; 5: 5.
18. Kimball SR, Orellana RA, O'Connor PM, et al. Endotoxin induces differential regulation of mTOR-dependent signaling in skeletal muscle and liver of neonatal pigs. Am J Physiol Endocrinol Metab 2003; 285(3): E637.